Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2013 Apr;27(2):289-301. doi: 10.1016/j.hoc.2013.01.008.

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.

Author information

1
Department of Internal Medicine III, Ulm University, Ulm 89081, Germany.

Abstract

Treatment of chronic lymphocytic leukemia has greatly advanced in the past few years since introduction of the fludarabine/cyclosphosphamide/rituximab regimen as first-line therapy. Nevertheless, 17p deletion represents a challenge because conventional treatment does not provide satisfactory results. 17p deletion and TP53 mutation are the major factors accounting for rapid disease progression, poor response to therapy, early relapse, and short survival. Allogeneic stem cell transplantation harbors curative potential but also considerable morbidity and mortality. Novel agents acting independently of the p53 signaling pathway, with favorable side-effect profiles, are promising. This review summarizes up-to-date knowledge about 17p deletion and the spectrum of treatment options.

PMID:
23561474
DOI:
10.1016/j.hoc.2013.01.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center